Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

Rhea-AI Summary

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology firm focused on upregulating protein expression with RNA-based therapies, will present at the virtual SVB Securities Global Biopharma Conference on February 14, 2023, at 4:20 p.m. ET. This presentation will be in a fireside chat format and will be webcast live, available on Stoke's website for 30 days post-event. Stoke's lead compound, STK-001, targets Dravet syndrome, a severe genetic epilepsy, while STK-002 is under development for autosomal dominant optic atrophy. The company is headquartered in Bedford, Massachusetts, with operations in Cambridge, Massachusetts.

BEDFORD, Mass.--(BUSINESS WIRE)-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the virtual SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 4:20 p.m. ET.

A live webcast of the presentation, which will be conducted in fireside chat format, will be available on the Investors & News section of Stoke’s website at https://investor.stoketherapeutics.com/ and can be accessed by following this Link. A replay of the webcast will be available for 30 days following the presentation.

About Stoke Therapeutics

Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines. Using Stoke’s proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Stoke’s first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Dravet syndrome is one of many diseases caused by a haploinsufficiency, in which a loss of ~50% of normal protein levels leads to disease. Stoke is pursuing the development of STK-002 for the treatment of autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Stoke’s initial focus is haploinsufficiencies and diseases of the central nervous system and the eye, although proof of concept has been demonstrated in other organs, tissues, and systems, supporting its belief in the broad potential for its proprietary approach. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow Stoke on Twitter at @StokeTx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005479/en/

Stoke Investor Contact:

Eric Rojas

Vice President, Investor Relations

IR@stoketherapeutics.com

617-312-2754

Source: Stoke Therapeutics, Inc.

FAQ

When will Stoke Therapeutics present at the SVB Securities Global Biopharma Conference?

Stoke Therapeutics will present on February 14, 2023, at 4:20 p.m. ET.

How can I access the Stoke Therapeutics presentation webcast?

The presentation can be accessed live on Stoke's website and will be available for replay for 30 days.

What is Stoke Therapeutics focusing on in its drug development?

Stoke Therapeutics focuses on upregulating protein expression to treat severe diseases, specifically targeting conditions caused by haploinsufficiency.

What is the lead product candidate of Stoke Therapeutics?

Stoke's lead product candidate is STK-001, which is in clinical testing for Dravet syndrome.

Where is Stoke Therapeutics located?

Stoke Therapeutics is headquartered in Bedford, Massachusetts, with additional offices in Cambridge, Massachusetts.